Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

Myeloma EHA 2025 preview

The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma. Myeloma Patients Europe (MPE) will be attending the congress to…

Read more

EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patients

On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is with bortezomib (a proteasome inhibitor) plus the steroid dexamethasone (BVd) in patients who have received at least one prior therapy.…

Read more

Register now to join the webinar “Living well with AL amyloidosis”

Myeloma Patients Europe (MPE) will host a webinar on “Living well with AL amyloidosis” on Thursday, 5 June 2025 from 17:00 – 18:00 CEST. Aimed at AL amyloidosis patients and patient advocates, the webinar will feature presentations on supportive care for patients. Prof. Dr. Monique Minnema, Haematologist at the University Medical Centre Utrecht, will focus…

Read more

In Memoriam of Reidar Nordby

It is with great sadness that we share the news of the passing of our friend, colleague, and fellow patient advocate, Reidar Nordby. With his passing, Myeloma Patients Europe (MPE) has lost not only a dear friend but also a valued Board member since 2023, who contributed to the growth and development of our organisation.…

Read more

European Commission approves linvoseltamab for the treatment of relapsed and refractory myeloma

On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when the results of other, larger clinical trials become available. This approval is based on the favourable recommendation issued by the…

Read more

EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patients

On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee responsible for opinions on all issues regarding medicinal products for human use. Based on these opinions, then the European Commission…

Read more
March

April 2026

May
MO
TU
WE
TH
FR
SA
SU
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
Events for 1st April
No Events
Events for 2nd April
No Events
Events for 3rd April
No Events
Events for 4th April
No Events
Events for 5th April
No Events
Events for 6th April
No Events
Events for 7th April
No Events
Events for 8th April
No Events
Events for 9th April
No Events
Events for 10th April
No Events
Events for 11th April
No Events
Events for 12th April
No Events
Events for 13th April
No Events
Events for 14th April
No Events
Events for 15th April
No Events
Events for 16th April
No Events
Events for 17th April
No Events
Events for 18th April
No Events
Events for 19th April
No Events
Events for 20th April
No Events
Events for 21st April
No Events
Events for 22nd April
No Events
Events for 23rd April
No Events
Events for 24th April
No Events
Events for 25th April
No Events
Events for 26th April
No Events
Events for 27th April
No Events
Events for 28th April
No Events
Events for 29th April
No Events
Events for 30th April
No Events